Organization and Significant Accounting Policies (Details)
|
|
12 Months Ended |
|
|
|
Jul. 21, 2014
USD ($)
$ / shares
shares
|
Dec. 31, 2016
shares
|
Sep. 02, 2014
item
|
Apr. 16, 2014
item
|
| FDA Warning Letter |
|
|
|
|
| Number of observations | item |
|
|
|
8
|
| Number of identified responses whose accuracy will be determined | item |
|
|
2
|
|
| Initial Public Offering |
|
|
|
|
| Conversion ratio |
|
1.75
|
|
|
| IPO |
|
|
|
|
| Initial Public Offering |
|
|
|
|
| Number of shares sold of common stock |
2,318,400
|
|
|
|
| Number of shares sold to the underwriter for the exercise of over-allotment option |
302,400
|
|
|
|
| Original issue price (in dollars per share) | $ / shares |
$ 6.25
|
|
|
|
| Net proceeds generated after deducting underwriting discounts and expenses | $ |
$ 12,400,000
|
|
|
|
| Underwriting discounts and expenses | $ |
$ 2,000,000
|
|
|
|
| Conversion ratio |
1
|
|
|
|
| Warrants up to the number of shares, underwriters can be purchase |
201,600
|
|
|
|
| Fair value of warrants | $ |
$ 611,000
|
|
|
|
| Exercise price of warrants (in dollars per share) | $ / shares |
$ 8.13
|
|
|
|
| Exercise price expressed as a percent of original issue price |
130.00%
|
|
|
|
| Number of warrants exercised |
|
20,000
|
|
|